Sudeep Pharma Limited (NSE:SUDEEPPHRM)

India · Delayed Price · Currency is INR

825.00

+22.70 (2.83%)

Jul 10, 2026, 3:29 PM IST

13.01% (1Y)

Market Cap	93.10B
Revenue (ttm)	6.42B +39.8%
Net Income	1.73B +29.8%
EPS	15.50 +26.2%
Shares Out	112.95M
PE Ratio	53.18
Forward PE	48.20
Dividend	1.50 (0.18%)
Ex-Dividend Date	n/a

Volume	170,060
Open	807.15
Previous Close	802.30
Day's Range	807.15 - 834.50
52-Week Range	524.05 - 894.45
Beta	n/a
Analysts	Sell
Price Target	730.00 (-19.58%)
Earnings Date	Aug 5, 2026

About Sudeep Pharma

Sudeep Pharma Limited manufactures and sells excipients and specialty ingredients for the pharmaceutical, food, and nutrition industries in United States, Europe, United Kingdom, and Latin America. The company provides mineral salts, such as calcium, zinc, iron, potassium, magnesium, sodium, and copper to a range of health-focused applications; and calcium carbonate, which is used as an active pharmaceutical ingredient for various therapeutic applications. It also offers micronutrient premixes, encapsulated ingredients, liposomal and spray-drie... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1989

Employees 740

Stock Exchange National Stock Exchange of India

Ticker Symbol SUDEEPPHRM

Full Company Profile

Financial Performance

In fiscal year 2026, Sudeep Pharma's revenue was 6.42 billion, an increase of 27.94% compared to the previous year's 5.02 billion. Earnings were 1.73 billion, an increase of 24.63%.

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for SUDEEPPHRM stock is "Sell." The 12-month stock price target is ₹730.00, which is a decrease of -19.58% from the latest price.

Price Target

₹730.00

(-19.58% downside)

Analyst Consensus: Sell

Stock Forecasts